logo

For the Inventor, By the Inventor

Doha, Qatar

Mohamed Elrayess

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Qatar University. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mohamed Elrayess. Retrieved from https://idiyas.com/inventor/mohamed-elrayess

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 1


Company Filing History:

goldMedal3 out of 115 
 
Qatar University
 patents

Years Active: 2024-2026

Loading Chart...
3 patents (USPTO):Explore Patents
1. 12517140 - Biomarkers for predicting intensive care unit stay duration for mechanically ventilated covid-19 patients (2026-01-06),
2. 12416007 - GATA3 inhibitors for treating insulin resistance (2025-09-16),
3. 11976282 - GATA3 inhibitors for the promotion of subcutaneous fat deposition (2024-05-07),

Title: Innovations by Inventor Mohamed Elrayess

Introduction

Mohamed Elrayess is a notable inventor based in Doha, Qatar. He has made significant contributions to the field of medical research, particularly in the treatment of insulin resistance and Type II diabetes. With a total of 3 patents, his work focuses on innovative methods and compositions that aim to improve health outcomes.

Latest Patents

Elrayess's latest patents include groundbreaking research on GATA3 inhibitors. The first patent details methods and compositions using dnayzme-based GATA3 inhibitors for treating insulin resistance. This invention aims to stimulate adipogenesis in vivo and promote fat redistribution. The second patent also revolves around GATA3 inhibitors, specifically for promoting subcutaneous fat deposition, further enhancing the treatment of insulin resistance and Type II diabetes.

Career Highlights

Currently, Mohamed Elrayess is affiliated with Qatar University, where he continues to advance his research and contribute to the academic community. His work is recognized for its potential impact on public health, particularly in addressing metabolic disorders.

Collaborations

Elrayess collaborates with Layla AlMANSOORI, a fellow researcher, to explore innovative solutions in their field. Their partnership exemplifies the importance of teamwork in scientific research.

Conclusion

In summary, Mohamed Elrayess is a pioneering inventor whose work on GATA3 inhibitors holds promise for treating insulin resistance and Type II diabetes. His contributions to medical research are significant and reflect his commitment to improving health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…